Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Philip Hess

Internal Medicine Tulsa, OK Medical Doctor

NPI 1750368924 CMS profile 34419

6465 S Yale Ave, Ste 704, Tulsa, OK 74136

Open in the dashboard

General payments

$3,392

167 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Philip Hess of Tulsa, OK is reported in the CMS Open Payments database as having received $3,392 across 167 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $273 13
2024 General $414 17
2023 General $1,366 60
2022 General $847 43
2020 General $82 6
2019 General $410 28

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Philip Hess
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Philip Hess were reported at $273. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Philip Hess Internal Medicine median Middle half National median
2019 $410 $159 $48–$570 $163
2020 $82 $119 $33–$402 $114
2021 $0 $135 $37–$521 $132
2022 $847 $141 $42–$496 $149
2023 $1,366 $149 $45–$519 $160
2024 $414 $154 $47–$537 $164
2025 $273 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Lilly USA, LLC $598 29 payments
  2. Bayer HealthCare Pharmaceuticals Inc. $364 15 payments
  3. Pfizer Inc. $360 21 payments
  4. GlaxoSmithKline, LLC. $335 9 payments
  5. AbbVie, Inc. $307 20 payments
  6. Janssen Pharmaceuticals, Inc $153 10 payments
  7. Astellas Pharma US Inc $147 5 payments
  8. AstraZeneca Pharmaceuticals LP $125 7 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $119 7 payments
  10. Horizon Therapeutics plc $110 1 payment
  11. Other $774 43 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,392 167 payments
Products named General payments · program years 2019–2025
  1. Kerendia $364 15 payments
  2. JARDIANCE $325 13 payments
  3. MOUNJARO $251 14 payments
  4. AREXVY $184 6 payments
  5. SHINGRIX $180 6 payments
  6. UBRELVY $166 10 payments
  7. XARELTO $153 10 payments
  8. QULIPTA $153 10 payments
  9. Veozah $147 5 payments
  10. ELIQUIS $127 9 payments
  11. Other $2,357 132 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 116 drugs

Part D claims

6,910

Median for Internal Medicine: 777

Drug cost

$607,627

Median for Internal Medicine: $73,373

Branded share of claims

20.6%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 120 $131,511
Jardiance Empagliflozin Brand 70 $78,153
Ozempic Semaglutide Brand 39 $58,232
Xarelto Rivaroxaban Brand 61 $58,091
Mounjaro Tirzepatide Brand 36 $41,369
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 40 $30,866
Tradjenta Linagliptin Brand 26 $19,929
Farxiga Dapagliflozin Propanediol Brand 17 $16,916
Atorvastatin Calcium Generic 585 $15,321
Myrbetriq Mirabegron Brand 20 $14,935

The 10 drugs with the highest cost, of 116 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 28 billing codes

Paid by Medicare

$41,695

Of which drugs: $6,109

Medicare patients

260

Average age 76

Services billed

1,613

122 women, 138 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Chronic kidney disease 40%
Arthritis 38%
Ischemic heart disease 30%
Diabetes 29%
Atrial fibrillation 19%
Cancer 18%
Heart failure 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90653 Office 45 45 $3,682

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SHINGRIX
  • GlaxoSmithKline, LLC. $123
$123 — —
MOUNJARO
  • Lilly USA, LLC $36
$36 36 —
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $31
$31 — —
GEMTESA
  • Sumitomo Pharma America, Inc. $29
$29 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $25
$25 17 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

167 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Oklahoma

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record